Leishmaniasis is a parasitic disease caused by infections of Leishmania spp.; It can be classified into cutaneous, mucocutaneous, or visceral forms. Currently ~12 million people in 98 countries infected with the disease. Visceral leishmaniasis (VL) is the most severe form of the disease and is almost always fatal if left untreated. VL is caused by Leishmania donovani and there is currently no vaccine available to prevent the disease. The primary goal of the project is to study the cell surface proteins of L. donovani to identify suitable antigens for the development of vaccines in the future.